Over 1000 professionals representing pharmaceutical/biopharmaceutical companies, CROs and multiple regulatory agencies convened at the 13th WRIB (Workshop on Recent Issues in Bioanalysis) on April 1-5, 2019 in New Orleans to discuss current topics of interest in Bioanalysis, Biomarkers, Immunogenicity and Gene Therapy. High Quality, better compliance to regulations and scientific excellence have always been the foundations of this workshop.
The 13th WRIB included 3 sequential Main Workshop days, 6 additional full-day Training Sessions that together spanned an entire week in order to allow exhaustive and thorough coverage of all major issues in bioanalysis, biomarkers, immunogenicity and gene therapy.
While the 13th WRIB continued its well-established tradition to provide Novel Solutions in Drug Discovery/Development and promote Innovation in Method Development in Bioanalysis, Biomarkers and Immunogenicity, the 2019 edition was also setting the stage to discuss 4 recently released guidance important to the industry with participating regulators:
Participating Regulators at the 13th WRIB again included all Major and Influential Regulatory Agencies in North America, Europe, Latin America, and Asia.
The 2019 White Paper in Bioanalysis from the 13th WRIB will be published on Journal Bioanaysis.
Like the previous editions, 13th WRIB was again
What made WRIB Special?
In this busy and fast paced environment, it is great to attend a conference that organizes everything for you so all you need to do is to focus on your learning: